文献速递复苏、休克与脓毒症呼吸衰竭与机械通气

新型寡核苷酸mRNA模拟物减轻失血诱导的急性肺损伤

A NOVEL OLIGONUCLEOTIDE MRNA MIMIC ATTENUATES HEMORRHAGE-INDUCED ACUTE LUNG INJURY.
PubMed 文献 · Shock · 2024-01-06
一句话结论小鼠失血性休克模型中,A 12(4 nmol/g)复苏液灌洗可显著降低血清损伤与炎症标志物并减轻肺组织损伤,作者认为可能为改善出血预后提供新思路。

研究在小鼠失血性休克模型(平均动脉压30 mmHg持续90 min,乳酸林格液复苏,输注量为失血量的2倍)中,比较复苏液含磷酸盐缓冲液(溶媒)与含A 12(4 nmol/g体重)的效果。复苏后4 h,A 12组血清乳酸脱氢酶、丙氨酸转氨酶、血尿素氮及TNF-α、IL-6水平显著降低,肺组织TNF-α、MIP-2、KC mRNA表达下降,肺组织学损伤评分、中性粒细胞浸润(Ly6G染色及髓过氧化物酶活性)和肺细胞凋亡均显著减轻。作者认为A 12能减轻失血性休克诱导的急性肺损伤,可能为开发改善出血预后的有效药物提供新视角。

要点

  • 小鼠失血性休克模型:平均动脉压30 mmHg持续90 min,复苏液输注量为失血量的2倍。
  • A 12以4 nmol/g体重加入乳酸林格液复苏,复苏后4 h评估。
  • A 12显著降低血清乳酸脱氢酶、丙氨酸转氨酶、血尿素氮及TNF-α、IL-6水平。
  • A 12显著降低肺组织TNF-α、MIP-2、KC mRNA表达及肺组织学损伤评分。
  • A 12显著减轻肺中性粒细胞浸润(Ly6G染色、髓过氧化物酶活性)和肺细胞凋亡。

适用人群与场景

  • 雄性小鼠失血性休克模型:受控出血使平均动脉压降至30 mmHg并维持90 min,随后以乳酸林格液复苏。

处置流程与药物剂量

  • 复苏液为含磷酸盐缓冲液(溶媒)或A 12(4 nmol/g体重)的乳酸林格液,输注量为失血量的2倍;复苏后4 h处死取材。

研究设计与关键结果

  • 研究类型为小鼠在体实验;雄性小鼠受控出血至平均动脉压30 mmHg持续90 min,复苏液输注量为失血量2倍,复苏后4 h评估。
  • A 12(4 nmol/g体重)组血清乳酸脱氢酶、丙氨酸转氨酶、血尿素氮及TNF-α、IL-6水平较溶媒组显著降低。
  • A 12组肺组织TNF-α、MIP-2、KC mRNA表达较溶媒组显著降低。
  • A 12组肺组织学损伤评分、中性粒细胞浸润(Ly6G染色及髓过氧化物酶活性)和肺细胞凋亡较溶媒组显著减轻。

证据类型、等级与局限

  • 证据类型:小鼠在体实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为A 12减轻失血性休克诱导的急性肺损伤的能力可能为开发改善出血预后的有效药物提供新视角。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Hemorrhagic shock (HS) is accompanied by a pronounced activation of the inflammatory response in which acute lung injury (ALI) is one of the most frequent consequences. Among the pivotal orchestrators of this inflammatory cascade, extracellular cold-inducible RNA-binding protein (eCIRP) emerges as a noteworthy focal point, rendering it as a promising target for the management of inflammation and tissue injury. Recently, we have reported that oligonucleotide poly(A) mRNA mimic termed A 12 selectively binds to the RNA binding region of eCIRP and inhibits eCIRP binding to its receptor TLR4. Furthermore, in vivo administration of eCIRP induces lung injury in healthy mice and that mouse deficient in CIRP showed protection from inflammation-associated lung injury. We hypothesize that A 12 inhibits systemic inflammation and ALI in HS. To test the impacts of A 12 on systemic and lung inflammation, extent of inflammatory cellular infiltration and resultant lung damage were evaluated in a mouse model of HS. Male mice were subjected to controlled hemorrhage with a mean arterial pressure of 30 mm Hg for 90 min and then resuscitated with Ringer's lactate solution containing phosphate-buffered saline (vehicle) or A 12 at a dose of 4 nmol/g body weight (treatment). The infusion volume was twice that of the shed blood. At 4 h after resuscitation, mice were euthanized, and blood and lung tissues were harvested. Blood and tissue markers of inflammation and injury were evaluated. Serum markers of injury (lactate dehydrogenase, alanine transaminase, and blood urea nitrogen) and inflammation (TNF-α, IL-6) were increased after HS and A 12 treatment significantly decreased their levels. A 12 treatment also decreased lung levels of TNF-α, MIP-2, and KC mRNA expressions. Lung histological injury score, neutrophil infiltration (Ly6G staining and myeloperoxidase activity), and lung apoptosis were significantly attenuated after A 12 treatment. Our study suggests that the capacity of A 12 in attenuating HS-induced ALI and may provide novel perspectives in developing efficacious pharmaceutics for improving hemorrhage prognosis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Hu Z, Li J, Zhang F, et al. A NOVEL OLIGONUCLEOTIDE MRNA MIMIC ATTENUATES HEMORRHAGE-INDUCED ACUTE LUNG INJURY. Shock. 2024. PMID: 38300836. doi:10.1097/SHK.0000000000002309

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。